Oncology

Prospective real-world evidence reinforces EndoPredict’s strong prognostic performance Three-year interim results from the prospective, international RESCUE study were presented at the ESMO Congress 2026 in Madrid. The findings demonstrate that EndoPredict (EPclin) risk groups were associated with significantly different outcomes in patients with hormone receptor-positive (HR+), HER2-negative early breast cancer. The RESCUE study (Reaching for

Expert Interview: “Quality of Life During Active Surveillance” Interview Partner: Prof. Dr. med. Axel Merseburger, Director of the Department of Urology, UKSH Campus Lübeck 1. What are the most common misconceptions about Active Surveillance? The biggest misconception is equating “surveillance” with “doing nothing.” Active surveillance is not the absence of treatment; it is a structured

Deciphering Lobular Breast Cancer: A Distinct Entity — Clinical Pitfalls, Biomarker Limitations, and Individualised Treatment Decisions Blog Navigating ER+HER2− Early Breast Cancer Meritxell Bellet, MD, PhD • Mariangela Gaudio, MDVall d’Hebron University Hospital / VHIO / SOLTI, Barcelona | Eurobio Scientific Webinar, 23 April 2026 Introduction: ILC as a Distinct Biological Entity The medical and

EndoPredict® expands laboratory accessibility through new CFX96™ Dx compatibility June 3, 2026 Eurobio Scientific announces a significant expansion in the laboratory implementation flexibility of EndoPredict, with the addition of compatibility with the CFX96™ Dx Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.), in combination with QIAGEN RNA extraction kits. In addition to the existing and fully